RXFP1 agonists

A compound having Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is halo, CN, C1-7 alkyl substituted with 0-3 R6, C2-7 alkenyl substituted with 0-3 R6, C2-7 alkynyl substituted with 0-3 R6, C3-6 cycloalkyl substituted with 0-3 R14, C3-6 cycloalkenyl substituted with 0-3 R14, aryl substituted with 0-3 R14, or a 4- to 6-membered heterocyclyl comprising 1-3 heteroatoms selected from O, S(═O)p, N, and NR14a and substituted with 0-3 R14;
• R2 is H or C1-3 alkyl;
• R3 is —NRaC(═O)R5, —NRaC(═O)(CRdRd)1-2R7, or —NRaC(═O)NRaR7;
• R4 is halo, CN, C1-4 alkyl substituted with 0-5 halo substituents, —OH, —OC1-4 alkyl substituted with 0-5 halo substituents, —S(═O)pRc, or aryl;
• R5 is C1-8alkyl substituted with 0-4 R11 or C3-6cycloalkyl substituted with 0-4 R8 and 0-2 R9,
• R6 is halo, OH, C3-6 cycloalkyl, or aryl;
• R7 is aryl substituted with 0-4 R8 and 0-2 R9;
• R8 is —ORb;
• R9 is halo, CN, phenyl substituted with 0-3 R10 and 0-2 R11, or 3- to 12-membered heterocyclyl comprising 1-5 heteroatoms selected from O, S(═O)p, N, and NR11a, and substituted with 0-3 R10 and 0-2 R11;
• R10 is halo, CN, or C1-4 alkyl;
• R11 is C1-3 alkyl substituted with 0-1 R13 and 0-1 R13, —ORb, —NRaRa, —NRaC(═O)Rb, —NRaC(═O)ORb, —NRaC(═O)NRaRa, —NRaS(═O)pRc, —C(═O)Rb, —C(═O)ORb, —C(═O)NRaRa, —C(═O)NRaS(═O)pRc, —OC(═O)Rb, —S(═O)pRc, —S(═O)pNRaRa, C3-10 carbocyclyl substituted with 0-5 Re, 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, N and NR15, and substituted with 0-5 Re;
• R11a is H, or C1-4 alkyl substituted with 0-2 Re;
• R12 is halo, —C(═O)ORb, —C(═O)NHRa, —C(═O)NHORb, or C1-4 alkyl substituted with 0-3 halo or OH substituents;
• R13 is —ORb, —NRaRa, —NRaC(═O)Rb, —NRaC(═O)ORb, —NRaS(═O)pRc, —NRaS(O)pNRaRa, —OC(═O)NRaRa, —OC(═O)NRaORb, —S(═O)pNRaRa, or —S(O)pRc;
• R14 is halo, CN, C1-4 alkyl substituted with 0-3 halo substituents, —OC1-4 alkyl substituted with 0-3 halo substituents, —(CH2)0-3—NRaRa, —(CH2)0-3-aryl substituted with 0-3 Re, —O-aryl substituted with 0-3 Rc, or —(CH2)0-3-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, and N, and substituted with 0-3 Re;
• R14a is H, C(═O)C1-4 alkyl, or C1-3 alkyl substituted with 0-3 aryl substituents substituted with 0-2 halo substituents;
• R15 is H, C1-3 alkyl, or aryl;
• R16 is C1-3 alkyl substituted with 0-1 Re, —C(═O)Rb, —C(═O)ORb, —C(═O)NRaRa, —C(═O)NRaS(═O)pRc, —OC(═O)Rb, —S(═O)pRc, or —S(═O)pNRaRa;
• Ra is H, C1-5 alkyl substituted with 0-5 Re, C2-5 alkenyl substituted with 0-5 Re, C2-5 alkynyl substituted with 0-5 Re, —(CH2)n—C3-10 carbocyclyl substituted with 0-5 Re, or —(CH2)n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, and N, and substituted with 0-5 Re;
• or Ra and Ra together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, and N, and substituted with 0-5 Re;
• Rb is H, C1-5 alkyl substituted with 0-5 Re, C2-3 alkenyl substituted with 0-5 Re, C2-5 alkynyl substituted with 0-5 Re, —(CH2), —C3-10 carbocyclyl substituted with 0-5 Re, or —(CH2)n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, and N, and substituted with 0-5 Re;
• Rc is C1-5 alkyl substituted with 0-5 Re, C2-5 alkenyl substituted with 0-5 Re, C2-5 alkynyl substituted with 0-5 Re, C3-6 carbocyclyl, or 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, and N;
• Rd is H, —ORb, or C1-5 alkyl substituted with 0-5 Re;
• Re is halo, CN, ═O, C1-6 alkyl substituted with 0-5 Rg, C2-6 alkenyl substituted with 0-5 Rg, C2-6 alkynyl substituted with 0-5 Rg, —(CH2)n—C3-10 carbocyclyl substituted with 0-5 Rg, —(CH2)n-3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, and N, and substituted with 0-5 Rg, —(CH2)nORf, —C(═O)ORf, —C(═O)NRfRf, —NRfC(═O)Rf, —S(═O)pRf, —NRfC(═O)ORf, —OC(═O)NRfRf, or —(CH2)nNRfRf;
• Rf is H, C1-5 alkyl, C3-6, cycloalkyl, or aryl;
• or Rf and Rf together with the nitrogen atom to which they are both attached form a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, and N;
• Rg is halo, CN, OH, C1-6 alkyl, C3-6 cycloalkyl, or aryl;
• n is zero, 1, 2, or 3;
• and
• p is zero, 1, or 2.